India, March 31 -- Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, recommending approval of a new Opdivo subcutaneous formulation developed with the company's ENHANZE technology.
The new cancer drug delivery method was tested across multiple solid tumor indications in the European Union, demonstrating a faster and more flexible treatment option and helping alleviating pressure on healthcare system resources.
The regulatory agency's positive opinion is based on positive results from the Phase 3 CheckMate -67T trial.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-156818950...